Restless Legs Syndrome (RLS)
15
0
0
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.7%
1 terminated out of 15 trials
92.9%
+6.4% vs benchmark
60%
9 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (15)
Effectiveness of Matrix Rhythm Therapy for Restless Legs Syndrome
Study on the Mechanism of Gut Microbiota Mediating Restless Legs Syndrome Through Iron Metabolism
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
Efficacy of Tyrosine in Restless Legs Syndrome
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects